Kessler Topaz Launches Securities Inquiry Into Medline Inc.
A 19% combined drop in share price over two months has triggered a formal investigation by Kessler Topaz Meltzer & Check, LLP. The Radnor-based law firm is scrutinizing Medline Inc. following disclosures of systemic FDA manufacturing violations and a subsequent reduction in the company’s full-year adjusted EBITDA guidance.
The regulatory scrutiny centers on a May 28, 2026, FDA warning letter, which detailed significant failures in Medline’s adherence to Current Good Manufacturing Practice regulations. Regulators specifically cited the company for inadequate cleaning protocols and a lack of thorough investigations into microbial contamination within finished drug products. This warning marked the second enforcement action against the firm in less than sixty days.
Market reaction to these operational failures was immediate. Medline stock fell more than 7% following the initial disclosure of the FDA violations. The decline deepened on August 5, 2026, when shares plummeted an additional 12% after management reported second-quarter financial results and lowered financial forecasts. Investors who purchased Class A common stock and sustained financial losses are now being encouraged to contact attorney Jonathan Naji to evaluate potential claims under federal securities laws.
Comments (0)
No comments yet. Be the first!